Innovative products

Our strategy in this realm is to employ our own IP and know-how in formulation and device technology to develop innovative aerosol-based products designed for eye, nasal, oral, and inhalation applications. These niche products allow for the safe and efficacious delivery of molecules previously approved for a different therapeutic indication and/or a different delivery route, for eg, oral tablets and injections (505(b)(2) strategy).   

Generic products

Our strategy for generics includes the development and commercialization of high-quality and cost-effective generic nasal sprays, nebulized solutions, and pMDI products. These products are all currently in different stages of development, with our first product launch scheduled for 2020.

Disease targets

• Pulmonary diseases (eg, asthma, COPD, cystic fibrosis, pulmonary hypertension)
• Inflammation and pain management (eg, migraine)
• Psychiatric conditions (eg, depression)
• Neurological conditions (eg, Parkinson’s disease)
• Cardiovascular diseases (eg, stroke, systemic embolism)